Atea reports positive topline results in Phase III hepatitis C study

Atea Pharmaceuticals has reported top line results from its Phase III C-BEYOND trial in North America, assessing the once-daily fixed-dose BEM/RZR combination for chronic HCV infection.

The post Atea reports positive topline results in Phase III hepatitis C study appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.